Fosun International Ltd., the flagship of the Chinese conglomerate that owns Club Mediterranee SA, signaled the company will announce information related to initial public offerings of its healthcare assets before the end of the year.
News about the matter and private-equity investments in health care assets should come out during the second half of the year, group Chairman Guo Guangchang said at a briefing Wednesday in Hong Kong. The conglomerate is parent to Shanghai Fosun Pharmaceutical Group Ltd., which trades in Hong Kong and mainland China.
Fosun is accelerating steps to improve its balance sheet, it said in an earnings statement Tuesday, as it seeks to raise its junk credit rating to investment grade. The company reported a 21 percent increase in net income as profit more than doubled at its investment businesses and industrial operations, offsetting a decline in earnings from insurance.
“Whether it is an IPO or private equity in the health sector, you will see us make some accomplishments in the second half,” Guo said. “Fosun Group has never stopped pushing for the IPO of subsidiaries to enhance our liquidity.”
Pharmaceutical and health businesses contributed about 29 percent of net income last year, the most after investments, which contributed about 38 percent. Fosun Pharmaceutical in July agreed to buy an 86 percent stake in Hyderabad, India-based Gland Pharma Ltd. for as much as $1.26 billion, adding injectable drugs to its product range and expanding its global reach. It’s purchasing the stake from KKR Floorline Investments Pte.
Billionaire Guo has said he’s modeling Fosun on Berkshire Hathaway Inc.’s insurance plus investment strategy. The company has become one of the most acquisitive Chinese firms over the past two years, buying insurance and hospitality assets including Ironshore Inc. and the Club Med resort operator.
The company is rated Ba3 by Moody’s Investors Service, three notches below investment grade.
- Fosun Plans to Sell as Much as $6 Billion in Assets to Raise Credit Rating
- Ironshore Files for IPO in U.S. After A.M. Best Review of Parent Firm Fosun
- China’s Fosun Looks at UK, Europe Investments on Brexit Volatility
- A.M. Best Removes Ironshore from ‘Under Review’ Status
- U.S. Treasury Unit Reviews Fosun’s Acquisition of Ironshore
- China’s Fosun Aims to Lead in Insurance, Tourism, Healthcare; Plans to Cut Debt
- China’s Fosun Weighs IPO for Ironshore, Just 4 Months After Acquiring Insurer
- China’s Fosun Completes Acquisition of Remaining 80% Interest in Ironshore
Was this article valuable?
Here are more articles you may enjoy.